// App-Quantinova.ai

: Dupilumab Efficacy in Type 2 Inflammatory Asthma: Liberty Asthma QUEST Study

Researchers

Presenter

  • Ian Douglas Pavord

Principal Investigators

  • J. Mark Fitzgerald

  • Guy Brusselle

  • Sally E. Wenzel

  • Klaus F. Rabe

  • William W. Busse

  • Alberto Papi

  • Megan S. Rice

  • Yamo Deniz

  • Paul Rowe

  • Nikhil Amin

  • Neil M.H. Graham

  • Ariel Teper

Medical Centers

  • NIHR Oxford Biomedical Research Centre, Oxford University, Oxford, United Kingdom.

  • Ghent University Hospital, Ghent, Belgium

  • University of Pittsburgh Asthma Institute at UPMC, Pittsburgh, United States of America

  • LungenClinic Grosshansdorf and Christian-Albrechts University Kiel (members of the German Center for Lung Research [DZL]), Grosshansdorf and Kiel, Germany,

  • UW Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, United States of America

  • University Hospital Santa Anna, Ferrara, Italy,

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States.

  • Sanofi US, Bridgewater, United States of America

Locations

  • United Kingdom

  • Canada

  • Belgium

  • United States

  • Germany

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT02414854

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved